Crinetics Pharmaceuticals, Inc.

CRNXNASDAQHealthcare● Active

$33.51

+$0.59(+1.79%)

Market Cap$3.5B

P/E Ratio—

52W High$57.99

52W Low$25.83

Avg Volume1.2M

Open$33.09

Beta0.24

Insider Trades Ownership Employees

Crinetics Pharmaceuticals, Inc. (CRNX) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · CRNX · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Crinetics Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

CRNX insider buying and selling by quarter

CRNX insider selling · CRNX insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

981K490K0

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · CRNX ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

CRNX executive sell shares · CRNX board member insider trading · CRNX insider trading SEC filing

Showing 71 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	222,200	—	—	626,978	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	111,100	—	—	515,878	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	222,200	—	—	439,005	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	111,100	—	—	404,778	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	222,200	—	—	223,200	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	222,200	—	—	216,805	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	80,000	—	—	136,805	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	111,100	—	—	112,100	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	111,100	—	—	111,100	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	80,000	—	—	80,000	Form 4
May 29, 2026	Struthers Richard Scott President & CEO · Director	Gift	111,100	—	—	1,000	Form 4
Apr 8, 2026	Knight Jeff E. Chief Dev. & Operating Officer	Option	19,336	$19.64	$380K	190,452	Form 4
Apr 8, 2026	Knight Jeff E. Chief Dev. & Operating Officer	Option	9,624	$20.02	$193K	171,116	Form 4
Apr 8, 2026	Knight Jeff E. Chief Dev. & Operating Officer	Option	49,474	$23.98	$1.19M⚡	161,492	Form 4
Apr 8, 2026	Knight Jeff E. Chief Dev. & Operating Officer	Sale	85,163	$40.10	$3.42M⚡	105,289	Form 4
Mar 16, 2026	Knight Jeff E. COO	Sale	5,950	$37.11	$221K	115,979	Form 4
Mar 16, 2026	Knight Jeff E. COO	Sale	3,961	$37.77	$150K	112,018	Form 4
Mar 16, 2026	Betz Stephen F. Chief Scientific Officer	Sale	6,371	$37.11	$236K	141,342	Form 4
Mar 16, 2026	Betz Stephen F. Chief Scientific Officer	Sale	4,241	$37.77	$160K	137,101	Form 4
Mar 16, 2026	Struthers Richard Scott President & CEO · Director	Sale	13,196	$37.11	$490K	413,563	Form 4
Mar 16, 2026	Struthers Richard Scott President & CEO · Director	Sale	8,785	$37.77	$332K	404,778	Form 4
Mar 12, 2026	Vivaldi Coelho Rogerio Director	Sale	4,477	$36.08	$162K	16,823	Form 4
Mar 12, 2026	Vivaldi Coelho Rogerio Director	Sale	523	$36.77	$19K	16,300	Form 4
Mar 3, 2026	Okey Stephanie Director	Sale	3,000	$39.67	$119K	13,300	Form 4
Mar 3, 2026	Schilke Tobin CFO	Sale	6,713	$39.67	$266K	78,121	Form 4

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

222,200

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

111,100

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

222,200

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

111,100

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

222,200

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

222,200

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

80,000

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

111,100

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

111,100

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

80,000

Price

—

Value

—

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Gift

Date

May 29

111,100

Price

—

Value

—

View Form 4 on SEC.gov

Knight Jeff E.

Chief Dev. & Operating Officer

Option

Date

Apr 8

19,336

Price

$19.64

Value

$380K

View Form 4 on SEC.gov

Knight Jeff E.

Chief Dev. & Operating Officer

Option

Date

Apr 8

9,624

Price

$20.02

Value

$193K

View Form 4 on SEC.gov

Knight Jeff E.

Chief Dev. & Operating Officer

Option

Date

Apr 8

49,474

Price

$23.98

Value

$1.19M ⚡

View Form 4 on SEC.gov

Knight Jeff E.

Chief Dev. & Operating Officer

Sale

Date

Apr 8

85,163

Price

$40.10

Value

$3.42M ⚡

View Form 4 on SEC.gov

Knight Jeff E.

COO

Sale

Date

Mar 16

5,950

Price

$37.11

Value

$221K

View Form 4 on SEC.gov

Knight Jeff E.

COO

Sale

Date

Mar 16

3,961

Price

$37.77

Value

$150K

View Form 4 on SEC.gov

Betz Stephen F.

Chief Scientific Officer

Sale

Date

Mar 16

6,371

Price

$37.11

Value

$236K

View Form 4 on SEC.gov

Betz Stephen F.

Chief Scientific Officer

Sale

Date

Mar 16

4,241

Price

$37.77

Value

$160K

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Sale

Date

Mar 16

13,196

Price

$37.11

Value

$490K

View Form 4 on SEC.gov

Struthers Richard Scott

President & CEO · Director

Sale

Date

Mar 16

8,785

Price

$37.77

Value

$332K

View Form 4 on SEC.gov

Vivaldi Coelho Rogerio

Director

Sale

Date

Mar 12

4,477

Price

$36.08

Value

$162K

View Form 4 on SEC.gov

Vivaldi Coelho Rogerio

Director

Sale

Date

Mar 12

523

Price

$36.77

Value

$19K

View Form 4 on SEC.gov

Okey Stephanie

Director

Sale

Date

Mar 3

3,000

Price

$39.67

Value

$119K

View Form 4 on SEC.gov

Schilke Tobin

CFO

Sale

Date

Mar 3

6,713

Price

$39.67

Value

$266K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About CRNX insider trading

CRNX insider trades

Crinetics Pharmaceuticals, Inc. (CRNX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Struthers Richard Scott (President & CEO · Director), Pizzuti Dana (Chief Med and Dev Officer), Knight Jeff E. (Chief Dev. & Operating Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. CRNX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Crinetics Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

CRNX insider trading · 5 questions

The insiders of Crinetics Pharmaceuticals, Inc. (CRNX) include executives and directors such as Struthers Richard Scott (President & CEO · Director), Pizzuti Dana (Chief Med and Dev Officer), Knight Jeff E. (Chief Dev. & Operating Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

CRNX board member insider tradingwho are CRNX insidersCRNX insider rosterCrinetics Pharmaceuticals, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026